Midodrine in the Recovery Phase of Septic Shock

• Status: Terminated
• Trial end date: 2018-05-02
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to investigate the role of oral midodrine in the recovery of septic shock. The investigators hypothesize that the oral drug can reduce central line days and ICU length of stay.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Virginia
• Treatments: Midodrine

Criteria

Inclusion Criteria:

• • Patients aged 18-99 years old

• Admitted to UVA medical ICU with diagnosis of septic shock.

Exclusion Criteria:

• Pregnant females, patients with childbearing potential will have urine pregnancy testing after consent

• Patients < 18 years

• Prisoners

• Patients already taking midodrine

• Patients with cirrhosis and Child-Pugh Class C (Child-Pugh score > 9)_

• Patients with Increased intraocular pressure and glaucoma

• Patients with allergy to midodrine

• Non-English speaking patients

• Patients without enteral access

• Patients where the attending physician does not feel MAP goal of > 65 mmHg is physiologically acceptable.